A trial of a new pancreatic cancer pill has shown major progress, offering fresh hope in the fight against one of the hardest cancers to treat.
The pill, called daraxonrasib, is a KRAS-inhibitor given together with chemotherapy. In a trial of 61 patients with newly diagnosed advanced pancreatic cancer, the treatment made cancer undetectable on scans in one in 12 patients, and halted tumour growth in 90% of patients. Those are striking numbers for a disease that has, for a long time, offered patients very few good options.
Pancreatic cancer is one of the most feared diagnoses in medicine. It is often found late, because it does not cause obvious symptoms in its early stages, and by the time it is discovered, it has often spread beyond the pancreas. Treatment options have been limited, and survival rates have been low compared with many other cancers. For patients and their families, a diagnosis of advanced pancreatic cancer has often meant a short time, and very few treatments that could change that.
That is why a trial like this one matters so much. It does not mean that pancreatic cancer is cured, and it does not mean that this pill will work for everyone. But it does mean that researchers have found something that can, in some patients, make the cancer disappear from scans, and in most patients, stop it from growing. For a disease where progress has been slow and painful, that is a genuine step forward.
To understand why this pill is different, it helps to know a little about how pancreatic cancer works. Many pancreatic cancers are driven by a gene called KRAS. When KRAS goes wrong, it tells cells to keep growing and dividing, even when they should stop. That is what makes a tumour grow. For many years, KRAS was considered undruggable, a target that scientists could see but could not hit. It was too smooth, too difficult for a drug to grab onto, and too important to healthy cells to block completely.
In recent years, that has started to change. Researchers have found ways to design drugs that can block KRAS, and daraxonrasib is one of them. It is a pill, which matters, because pills are easier to take than many cancer treatments, and they can be taken at home rather than in a hospital. In this trial, it was given together with chemotherapy, the standard treatment for advanced pancreatic cancer, and the combination appears to have worked better than chemotherapy alone.
The numbers tell the story. In 61 patients with newly diagnosed advanced pancreatic cancer, the cancer became undetectable on scans in one in 12 patients. That does not necessarily mean the cancer is gone completely. Scans can only see so much, and cancer can hide in places that a scan cannot reach. But it does mean that, for those patients, there was no visible tumour left to see, which is a remarkable result for advanced pancreatic cancer.
Even more striking is the second number: tumour growth was halted in 90% of patients. That means that for nine out of ten people in the trial, the cancer stopped growing. It did not necessarily shrink, and it did not necessarily disappear, but it stopped getting worse. For a disease that usually grows quickly, and for patients who have been told that their cancer is advanced, stopping the growth is a meaningful achievement. It can mean more time, more time feeling well, and more time with family.
It is important to be careful about what these numbers do and do not mean. This was a trial, not a final approval, and the patients in it were newly diagnosed with advanced pancreatic cancer. That is a specific group, and the results may not apply to everyone with pancreatic cancer. The trial was also relatively small, with 61 patients, and larger trials will be needed to confirm the results, to work out who benefits most, and to understand the side effects.
Side effects matter, because cancer treatments can be harsh. A pill that stops a tumour from growing is only useful if patients can tolerate it, if they can take it for a long time, and if the side effects do not make their lives worse. The trial will have looked at that, but the full picture will only become clear as more patients are treated, and as the treatment is used for longer.
For patients, the news will be both hopeful and frustrating. Hopeful, because it shows that progress is possible, and that researchers are finding new ways to attack this disease. Frustrating, because a trial result is not the same as a treatment you can get tomorrow. It will take time for larger trials to be completed, for regulators to review the evidence, and for the drug to become available to patients outside a trial. That waiting is hard, especially for people who are living with pancreatic cancer now.
For the researchers, the next steps are clear. They will need to test daraxonrasib in larger groups of patients, to see if the results hold up, and to work out the best dose, the best combination with chemotherapy, and the best way to identify which patients are most likely to benefit. They will also need to watch for side effects over a longer period, and to see how long the benefit lasts. Does the cancer stay halted, or does it eventually start growing again? Does the pill work better in some patients than in others, and if so, why? Those are the questions that will shape the next phase of research.
Pancreatic cancer still kills far too many people, and it still needs far more research, far more funding, and far more attention. A single trial, even a promising one, will not change that overnight. But for the 61 patients in this trial, and for their families, the results will have meant something real: a scan with no visible cancer, a tumour that stopped growing, and a little more time. And for everyone else facing this disease, it is a reason to hope that the next few years will bring more progress, and more options, than the last few decades did.